Diarrhea is a common complication of high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The frequent and prolonged use of multiple antibiotics in this setting can predispose to infection with toxigenic Clostridium difficile and the development of pseudomembranous colitis. Anti-motility agents are usually not administered in this setting until C. difficile infection has been excluded. The objective of this study was to determine the incidence of C. difficile toxin (CDT) positivity at the time of initial diarrhea in HSCT recipients, and to see if the practice of ensuring negative CDT assays prior to initiating symptomatic management of diarrhea needs modification. One hundred and nineteen patients with malignant diseases undergoing autologous or allogeneic HSCT were studied to determine the incidence of diarrhea and CDT positivity with initial diarrhea. One hundred and nine (91%) had diarrhea. Of these, only seven (6%) were CDT+ at the time of initial diarrhea. The median interval between onset of diarrhea and starting symptomatic antidiarrheal therapy was 1 day. There were no significant differences between the patients with CDT+ diarrhea and the others in terms of timing or severity of diarrhea, number or duration of antibiotic usage, or leukocyte count. The infection resolved in all patients with metronidazole therapy. Our data suggest that the incidence of CDT+ diarrhea is low in HSCT recipients. Concern about C. difficile infection should not delay symptomatic therapy of initial diarrhea in HSCT recipients.
The period following hematopoietic stem cell transplantation (HSCT) is associated with a number of complications including infection, mucositis, and diarrhea. Clostridium difficile is the cause of approximately one-quarter of all antibiotic-associated diarrheas, and is the most common cause of nosocomial diarrhea. 1 The development of C. difficile-associated diarrhea is related to the disruption of normal bowel flora and subsequent colonization with C. difficile. This occurs with the use of broad-spectrum antimicrobial agents, antineoplastic agents, and mucositis; risk factors which are prominent in patients undergoing HSCT.
The diagnosis of toxigenic (pathogenic) C. difficile infection often requires evaluation of serial stool samples by ELISA for the presence of toxin A.
1 For this reason, many patients are not treated symptomatically until multiple stool specimens have been found to be negative for C. difficile toxin (CDT). This results in significant, and potentially avoidable, morbidity in these patients.
There have been a few studies of C. difficile infections in HSCT recipients. [2] [3] [4] [5] However, none has focused specifically on C. difficile infections in the early post-transplant period, or symptomatic management. We sought to determine the incidence of CDT positivity at the time of initial diarrhea in autologous and allogeneic HSCT recipients.
Patients and methods
The records of 119 patients undergoing HSCT in the Division of Hematology/Oncology of the Northwestern University Medical School and the Northwestern Memorial Hospital (NMH) between July 1998 and June 2000 were reviewed. Diarrhea was defined as greater than three loose stools in a 24 h period for 2 consecutive days. The conditioning regimens employed were standard and of conventional intensity. Table 1 shows patient characteristics.
Ciprofloxacin or trimethoprim-sulfomethoxazole were used prophylactically. This was replaced with an antiPseudomonas ␤-lactam agent and an aminoglycoside at the time of neutropenic fever. Patients also received antiviral agents (usually acyclovir) and anti-fungal agents (fluconazole or itraconazole) prophylactically.
All patients with diarrhea had a minimum of one diarrheal stool sample evaluated for the presence of toxin A. The presence of C. difficile was analyzed using ELISA for toxin A. Patients found to have toxigenic C. difficile by ELISA or culture were considered CDT+. Categorical data were compared using the 2 test and continuous variables using the Wilcoxon rank-sum test.
Results
Diarrhea was seen in 109 of the 119 patients (91%). CDT+ diarrhea was seen in seven patients (6.4%; 95% CI: 1.8-11.0). Almost 80% of patients had grade 1 diarrhea (NCI Common Toxicity Criteria). 6 As Table 2 shows, there were no obvious risk factors for those patients who developed CDT+ diarrhea.
Four patients were started on empiric metronidazole therapy at the time of initial diarrhea based upon clinical suspicion of C. difficile. None of these patients was subsequently proven to have CDT+ diarrhea. All patients with CDT+ diarrhea had an excellent response to metronidazole therapy, and recovered without recurrence, prolongation of hospital stay, or other complications. Table 2 Clinical characteristics of patients with CDT+ diarrhea and all other patients with diarrhea. Values represent medians and ranges
CDT+ patients
All other patients P (n = 7) (n = 102)
Time to diarrhea (day 0 = day of transplant) Day +1 (Ϫ3 to +7) Day +2 (Ϫ6 to +13) 0.81 Days to starting anti-diarrheal agents In general, patients were not treated symptomatically with anti-motility agents until at least one stool toxin A assay was negative. Of the 68 patients treated with antimotility agents, 15 of 68 (22%) were symptomatically managed at the onset. The remainder had persistent, untreated diarrhea for 1-6 days (median 1 day) until anti-motility agents were administered.
Discussion
Our findings indicate that the incidence of CDT+ diarrhea at the time of initial diarrhea in HSCT patients is low because the high incidence of diarrhea in the early posttransplant period is likely related to the effects of the conditioning therapy. The number of patients with CDT+ diarrhea in our study population was too small to identify any clinical factors predictive of CDT+ diarrhea.
Symptomatic management of bowel hypermotility with opiates, binding agents, and anti-motility drugs can resolve the discomfort associated with diarrhea in the post-HSCT period. However, concern about C. difficile colitis and the increased morbidity and mortality inherent in not treating pseudomembranous colitis often results in delay in symptomatic management of diarrhea.
Our data suggest that since C. difficile infection is an uncommon occurrence early after HSCT, patients can be started on anti-motility therapy immediately after obtaining a stool sample -without awaiting CDT assay results. This clinical rule of thumb is clearly not applicable during an outbreak of C. difficile.
Four prior retrospective studies have focused on C. difficile-associated diarrhea in HSCT recipients. [2] [3] [4] [5] These studies evaluated diarrhea occurring any time after HSCT up to 100 days after the transplant. The incidence of CDT+ diarrhea in these series ranged from 4% to 13%.
Three studies have evaluated the etiology of diarrhea after HSCT. [7] [8] [9] Yolken et al 7 found the presence of CDT+ stool in nine of 78 patients (11.5%). However, they examined stool samples twice weekly regardless of symptoms, and of the nine patients found to be CDT+, only five had diarrhea. Cox et al 8 found CDT+ stools in only six of 150 (4.1%) diarrheal episodes in HSCT patients. Van Kraaij et al 9 found the incidence of diarrhea to be 79% and 47% in allogeneic and autologous HSCT patients, respectively. However, only 4% of the cases were secondary to the presence of C. difficile toxin.
We have chosen to look at diarrhea occurring early after HSCT because the incidence and etiology of diarrhea occurring after the first 2-3 weeks is clearly going to be different from the early episodes. Early diarrhea is most likely to be related to regimen-related toxicity. Since mucosal injury resulting from the conditioning regimen has usually healed after the first 2-3 weeks, diarrhea occurring later is likely to be due to other causes. Since patients have also been receiving antimicrobial therapy for longer (after the first 2-3 weeks), diarrhea occurring later in the course of HSCT may have a higher likelihood of being CDT+; particularly in units with a higher overall prevalence of C. difficile.
Our study confirms the low incidence of C. difficile infections post transplant. However, none of the other studies has focused on the seemingly trivial issue of symptomatic management of diarrhea. This common transplant-related morbidity is very distressing for patients. Based on our evaluation, it appears unnecessary to withhold anti-motility agents from patients at the time of the first episode of diarrhea post transplant. While stool samples should be checked for CDT, symptomatic management should begin immediately. We have modified our practice accordingly for diarrhea occurring early after HSCT.
